蒙脱石混悬液
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 4 applicationsNo longer listed under review: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Chemical-drug catalogue
Loaded records: 0 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 7 distinct approval numbers and 7 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 合肥远志医药科技开发有限公司 | 国药准字H20265718 | 10g:3g | 乙 | XA07BCM081X002010185197 | NHSA |
| 安徽永生堂药业有限责任公司 | 国药准字H20255891 | 10克:3克 | 乙 | XA07BCM081X002010104363 | NHSA |
| 南京海纳制药有限公司 | 国药准字H20255212 | 10g:3g | 乙 | XA07BCM081X002010180537 | NHSA |
| 成都归合科技有限公司 | 国药准字H20253808 | 10克:3克 | 乙 | XA07BCM081X002010184528 | NHSA |
| 四川天杏汇医药科技有限公司 | 国药准字H20256473 | 10克:3克 | 乙 | XA07BCM081X002010185049 | NHSA |
| 安徽永生堂药业有限责任公司 | 国药准字H20255891 | 10克:3克 | 乙 | XA07BCM081X002010204363 | NHSA |
| 成都归合科技有限公司 | 国药准字H20253808 | 10克:3克 | 乙 | XA07BCM081X002010284528 | NHSA |
| 四川天杏汇医药科技有限公司 | 国药准字H20256473 | 10克:3克 | 乙 | XA07BCM081X002010285049 | NHSA |
| 安徽永生堂药业有限责任公司 | 国药准字H20255891 | 10克:3克 | 乙 | XA07BCM081X002010304363 | NHSA |
| 南京海纳制药有限公司 | 国药准字H20255212 | 10g:3g | 乙 | XA07BCM081X002010380537 | NHSA |
| 成都归合科技有限公司 | 国药准字H20253808 | 10克:3克 | 乙 | XA07BCM081X002010384528 | NHSA |
| 四川天杏汇医药科技有限公司 | 国药准字H20256473 | 10克:3克 | 乙 | XA07BCM081X002010385049 | NHSA |
| 安徽永生堂药业有限责任公司 | 国药准字H20255891 | 10克:3克 | 乙 | XA07BCM081X002010404363 | NHSA |
| 南京海纳制药有限公司 | 国药准字H20255212 | 10g:3g | 乙 | XA07BCM081X002010480537 | NHSA |
| 成都归合科技有限公司 | 国药准字H20253808 | 10克:3克 | 乙 | XA07BCM081X002010484528 | NHSA |
| 南京白敬宇制药有限责任公司 | 国药准字H20060834 | 90ml:9g | 乙 | XA07BCM081X002010101554 | NHSA |
| IPSEN Consumer HealthCare | 国药准字HJ20220007 | 10克:3克 | 乙 | XA07BCM081X002010183508 | NHSA |
| 南京白敬宇制药有限责任公司 | 国药准字H20060834 | 90ml:9g | 乙 | XA07BCM081X002020101554 | NHSA |
| 南京白敬宇制药有限责任公司 | 国药准字H20060834 | 90ml:9g | 乙 | XA07BCM081X002030101554 | NHSA |
| 南京白敬宇制药有限责任公司 | 国药准字H20060834 | 90ml:9g | 乙 | XA07BCM081X002040101554 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 31 filings and 31 distinct first applicants.
Generic 29 · Import re-registration 1 · Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 浙江高跖医药科技股份有限公司;南京海纳制药有限公司 | CYHS2504165 | Generic | 2025/12/04 | Not stated by source | CDE |
| 山东华铂凯盛生物科技有限公司;南京海纳制药有限公司 | CYHS2501498 | Generic | 2025/04/19 | Not stated by source | CDE |
| 扬州市三药制药有限公司 | CYHS2503540 | Generic | 2025/09/28 | Not stated by source | CDE |
| MAYOLY PHARMA FRANCE;PHARMATIS | JYHZ2600220 | Import re-registration | 2026/09/15 | Not stated by source | CDE |
| 江西普丽尔药业有限公司 | CYHS2602066 | Generic | 2026/08/20 | Not stated by source | CDE |
| 江西施美药业股份有限公司 | CYHS2601637 | Generic | 2026/07/08 | Not stated by source | CDE |
| 重庆国泰康宁制药有限责任公司 | CYHS2601363 | Generic | 2026/06/10 | Not stated by source | CDE |
| 山东新华制药股份有限公司;安徽永生堂药业有限责任公司 | CYHS2601217 | Generic | 2026/06/01 | Not stated by source | CDE |
| 华润江中药业股份有限公司 | CYHS2601094 | Generic | 2026/05/13 | Not stated by source | CDE |
| 北京诚济制药股份有限公司 | CYHS2600805 | Generic | 2026/04/09 | Not stated by source | CDE |
| 辽宁大熊制药有限公司 | CYHS2600532 | Generic | 2026/02/26 | Not stated by source | CDE |
| 重庆世森医药科技有限公司;陕西汉江药业集团股份有限公司 | CYHS2600257 | Generic | 2026/01/23 | Not stated by source | CDE |
| 大玮（安徽）药业有限公司;安徽永生堂药业有限责任公司 | CYHS2504525 | Generic | 2026/01/04 | Not stated by source | CDE |
| 山东现代医药科技有限公司;浙江赛默制药有限公司 | CYHS2504412 | Generic | 2025/12/26 | Not stated by source | CDE |
| 黑龙江中桂制药有限公司 | CYHS2504244 | Generic | 2025/12/11 | Not stated by source | CDE |
| 河北宏鑫堂药业有限公司;河北山姆士药业有限公司 | CYHS2503824 | Generic | 2025/10/29 | Not stated by source | CDE |
| 瑞海医药科技（山东）有限公司;安徽永生堂药业有限责任公司 | CYHS2503709 | Generic | 2025/10/16 | Not stated by source | CDE |
| 杭州和泽坤元药业有限公司;广西南宁百会药业集团有限公司 | CYHS2503537 | Generic | 2025/09/28 | Not stated by source | CDE |
| 湖南华纳大药厂股份有限公司 | CYHS2503253 | Generic | 2025/09/04 | Not stated by source | CDE |
| 浙江百代医药科技有限公司;浙江赛默制药有限公司 | CYHS2502997 | Generic | 2025/08/15 | Not stated by source | CDE |
| 浙江远力健药业有限责任公司 | CYHS2502683 | Generic | 2025/07/24 | Not stated by source | CDE |
| IPSEN Consumer HealthCare;Beaufour Ipsen Industrie | JYHB2500372 | Supplement | 2025/07/17 | Not stated by source | CDE |
| 海南倍吉康医药科技有限公司;华益泰康药业股份有限公司 | CYHS2502337 | Generic | 2025/07/02 | Not stated by source | CDE |
| 浙江恒研医药科技有限公司;浙江赛默制药有限公司 | CYHS2502324 | Generic | 2025/06/30 | Not stated by source | CDE |
| 广东江正药业有限公司;广西南宁百会药业集团有限公司 | CYHS2502041 | Generic | 2025/06/10 | Not stated by source | CDE |
| 哈尔滨誉衡制药有限公司 | CYHS2501858 | Generic | 2025/05/23 | Not stated by source | CDE |
| 吉林省博大伟业制药有限公司 | CYHS2501447 | Generic | 2025/04/16 | Not stated by source | CDE |
| 湖北午时药业股份有限公司 | CYHS2500980 | Generic | 2025/03/08 | Not stated by source | CDE |
| 广西维威制药有限公司 | CYHS2401166 | Generic | 2024/04/18 | Not stated by source | CDE |
| 安徽新世纪药业有限公司 | CYHS2602664 | Generic | 2026/10/30 | Not stated by source | CDE |
| 山东仙河药业有限公司 | CYHS2602701 | Generic | 2026/11/05 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 11 filings and 11 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江西普丽尔药业有限公司 | CYHS2602066 | Generic | 2026/08/20 | Not stated by source | CDE |
| 江西施美药业股份有限公司 | CYHS2601637 | Generic | 2026/07/08 | Not stated by source | CDE |
| 重庆国泰康宁制药有限责任公司 | CYHS2601363 | Generic | 2026/06/10 | Not stated by source | CDE |
| 山东新华制药股份有限公司;安徽永生堂药业有限责任公司 | CYHS2601217 | Generic | 2026/06/01 | Not stated by source | CDE |
| 华润江中药业股份有限公司 | CYHS2601094 | Generic | 2026/05/13 | Not stated by source | CDE |
| 北京诚济制药股份有限公司 | CYHS2600805 | Generic | 2026/04/09 | Not stated by source | CDE |
| 辽宁大熊制药有限公司 | CYHS2600532 | Generic | 2026/02/26 | Not stated by source | CDE |
| 重庆世森医药科技有限公司;陕西汉江药业集团股份有限公司 | CYHS2600257 | Generic | 2026/01/23 | Not stated by source | CDE |
| 大玮（安徽）药业有限公司;安徽永生堂药业有限责任公司 | CYHS2504525 | Generic | 2026/01/04 | Not stated by source | CDE |
| 安徽新世纪药业有限公司 | CYHS2602664 | Generic | 2026/10/30 | Not stated by source | CDE |
| 山东仙河药业有限公司 | CYHS2602701 | Generic | 2026/11/05 | Not stated by source | CDE |
API registrations
Non-component matches: 15 companies with A status and 2 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 蒙脱石 | 四川维奥制药有限公司 | Y20200000762 | A | Exact ingredient | 2026/03/21 | CDE |
| 蒙脱石 | Ipsen Pharma | Y20190009971 | A | Exact ingredient | — | CDE |
| 蒙脱石 | 海南先声药业有限公司 | Y20190009512 | A | Exact ingredient | 2025/02/28 | CDE |
| 蒙脱石 | 山东颐和制药有限公司 | Y20190008450 | A | Exact ingredient | 2025/05/13 | CDE |
| 蒙脱石 | 山东宏济堂制药集团股份有限公司 | Y20190007250 | A | Exact ingredient | — | CDE |
| 蒙脱石 | 北京金城泰尔制药有限公司 | Y20190007141 | A | Exact ingredient | 2023/03/24 | CDE |
| 蒙脱石 | 河南蓝图制药有限公司 | Y20190006622 | A | Exact ingredient | — | CDE |
| 蒙脱石 | 南京易亨制药有限公司 | Y20190006076 | A | Exact ingredient | — | CDE |
| 蒙脱石 | 浙江仟源海力生制药有限公司 | Y20190002846 | A | Exact ingredient | 2024/10/31 | CDE |
| 蒙脱石 | 山东绿叶制药有限公司 | Y20190002185 | A | Exact ingredient | 2024/07/26 | CDE |
| 蒙脱石 | 山东仙河药业有限公司 | Y20190001592 | A | Exact ingredient | 2025/01/09 | CDE |
| 蒙脱石 | 山西康欣药业有限公司 | Y20190001378 | A | Exact ingredient | 2024/07/27 | CDE |
| 蒙脱石 | 海南先声药业有限公司 | Y20190000520 | A | Exact ingredient | 2025/05/20 | CDE |
| 蒙脱石 | 海南先声药业有限公司 | Y20180001015 | I | Exact ingredient | 2019/07/31 | CDE |
| 蒙脱石 | MAYOLY PHARMA FRANCE | Y20170001962 | A | Exact ingredient | 2026/05/20 | CDE |
| 蒙脱石 | 湖南华纳大药厂股份有限公司 | Y20170000501 | A | Exact ingredient | 2023/11/04 | CDE |
| 蒙脱石 | 烟台瑞东科技发展有限公司 | Y20170000480 | A | Exact ingredient | — | CDE |
| 蒙脱石 | 山东京卫制药有限公司 | Y20170000022 | I | Exact ingredient | — | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/09 06:35. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/05No longer listed under review
济南同路医药科技发展有限公司;广西南宁百会药业集团有限公司
CYHS2501503
Fact date: 2026/11/05 · Site observation date: 2026/11/05
Accepted: 2025/04/22
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/11/05Accepted
-
2026/10/30Accepted
-
2026/09/15Accepted
MAYOLY PHARMA FRANCE;PHARMATIS
JYHZ2600220
Fact date: 2026/09/15 · Site observation date: 2026/10/22
View source ↗ -
2026/08/20Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/09 06:38
- Chemical-drug catalogue
- Last successful update: 2026/11/09 06:35
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/09 06:36
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/08 18:30
First index-page publication dates: 2026-10-22 to 2026-11-06; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/09 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the initial backfill cohort. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 0/30; discovered pending details: 7. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to 蒙脱石混悬液
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Monthly subscription
Ongoing tracking for selected drugs
¥200/ month · pilot price
- A competitive ledger for up to 10 drugs, updated with daily data and available historical comparisons.
- Collected changes routed to designated responsible roles with the daily scheduled send.
- A forwardable weekly project-change digest, with sources for each record.
- Source dates and coverage gaps shown when collection is incomplete.
This form records an activation request; it does not charge or activate a subscription. History begins with records actually accumulated by this site. Scope is confirmed before activation.